Статті в журналах з теми "Predicting molecular response in CML"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Predicting molecular response in CML".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Wolf, Dominik, and Sieghart Sopper. "Molecular response prediction in CML: novel ideas?" Oncotarget 8, no. 46 (September 19, 2017): 80105–6. http://dx.doi.org/10.18632/oncotarget.21049.
Повний текст джерелаWolf, Dominik, and Sieghart Sopper. "Correction: Molecular response prediction in CML: novel ideas?" Oncotarget 9, no. 88 (November 9, 2018): 35871. http://dx.doi.org/10.18632/oncotarget.26360.
Повний текст джерелаAttili, S. V., P. Bapsy, D. Lokanatha, K. Govindababu, J. George, L. A. Jacob, H. K. Dadhich, and G. Anupama. "Are skin reactions a surrogate marker in predicting response to therapy in patients with chronic myeloid leukemia receiving imatinib?" Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 17539. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.17539.
Повний текст джерелаHu, Shiwei, Dan Chen, Xiaofei Xu, Lan Zhang, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Jie Jin, and Jian Huang. "Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study." Cancers 14, no. 23 (November 23, 2022): 5752. http://dx.doi.org/10.3390/cancers14235752.
Повний текст джерелаGlauche, Ingmar, Christoph Baldow, Sabine Fröhlich, Philipp Schulze, Amit Roy, Milayna Subar, Xiaoning Wang, and Ingo Roeder. "Model-Based Characterization of the Molecular Response Dynamics of Tyrosine Kinase Inhibitor (TKI)-Treated CML Patients – a Comparison of Imatinib and Dasatinib First-Line Therapy." Blood 124, no. 21 (December 6, 2014): 4562. http://dx.doi.org/10.1182/blood.v124.21.4562.4562.
Повний текст джерелаDybko, Jarosław, Bożena Jaźwiec, Olga Haus, Donata Urbaniak-Kujda, Katarzyna Kapelko-Słowik, Tomasz Wróbel, Tomasz Lonc, et al. "The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience." Disease Markers 2016 (2016): 1–5. http://dx.doi.org/10.1155/2016/7531472.
Повний текст джерелаBanjar, Haneen R., and Enaam Alsobhi. "Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib." International Scholarly Research Notices 2017 (February 13, 2017): 1–6. http://dx.doi.org/10.1155/2017/1076493.
Повний текст джерелаHaznedaroglu, Ibrahim C. "MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)." Mediterranean Journal of Hematology and Infectious Diseases 6, no. 1 (December 31, 2013): e2014009. http://dx.doi.org/10.4084/mjhid.2014.009.
Повний текст джерелаSopper, Sieghart, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjørn T. Gjertsen, et al. "Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia." Journal of Clinical Oncology 35, no. 2 (January 10, 2017): 175–84. http://dx.doi.org/10.1200/jco.2016.67.0893.
Повний текст джерелаde Lavallade, Hugues, Jane F. Apperley, Jamshid S. Khorashad, Dragana Milojkovic, Alistair G. Reid, Marco Bua, Richard Szydlo, et al. "Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis." Journal of Clinical Oncology 26, no. 20 (July 10, 2008): 3358–63. http://dx.doi.org/10.1200/jco.2007.15.8154.
Повний текст джерелаCea, Michele, Antonia Cagnetta, Gabriella Cirmena, Anna Garuti, Ilaria Rocco, Claudia Palermo, Ivana Pierri, et al. "Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment." Blood 116, no. 21 (November 19, 2010): 1215. http://dx.doi.org/10.1182/blood.v116.21.1215.1215.
Повний текст джерелаMichimata, Daigo, Kazunori Murai, Yasuro Miyairi, Yoshiaki Okano, Yuuzou Suzuki, Hiroyuki Hamada, Akiyoshi Sato, et al. "The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP." Blood 134, Supplement_1 (November 13, 2019): 2928. http://dx.doi.org/10.1182/blood-2019-125066.
Повний текст джерелаWhite, Deborah, Verity Saunders, A. Bruce Lyons, Susan Branford, Andrew Grigg, L. Bik To, and Timothy Hughes. "In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML." Blood 106, no. 7 (October 1, 2005): 2520–26. http://dx.doi.org/10.1182/blood-2005-03-1103.
Повний текст джерелаLee, Ha Yeon, Su Jin Lee, Boram Ha, Jun Ho Yi, Chul Won Jung, Dae-Young Kim, Je-Hwan Lee, et al. "Multicenter Retrospective Study on the Development of Peripheral Lymphocytosis During Second-Line Dasatinib Therapy for Chronic Myeloid Leukemia." Blood 116, no. 21 (November 19, 2010): 2275. http://dx.doi.org/10.1182/blood.v116.21.2275.2275.
Повний текст джерелаEngler, Jane R., Amity Frede, Verity Saunders, Andrew Zannettino, Deborah L. White, and Timothy P. Hughes. "The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells." Blood 116, no. 15 (October 14, 2010): 2776–78. http://dx.doi.org/10.1182/blood-2010-01-267013.
Повний текст джерелаSaussele, Susanne, Michael Lauseker, Verena Hoffmann, Ulrike Proetel, Benjamin Hanfstein, Gabriela M. Baerlocher, Dominik Heim, et al. "Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,." Blood 118, no. 21 (November 18, 2011): 3762. http://dx.doi.org/10.1182/blood.v118.21.3762.3762.
Повний текст джерелаAlaiya, Ayodele, Naeem A. Chaudhri, Hafiz Malhan, Tarek Owaidah, Zakia Shinwari, Jonathan Fox, Fahad Alsharif, et al. "Proteomics–Based Approach Predicts Molecular Response and Stratifies Responders to Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) Patients." Blood 124, no. 21 (December 6, 2014): 4556. http://dx.doi.org/10.1182/blood.v124.21.4556.4556.
Повний текст джерелаFujioka, Yuki, Hiroyoshi Nishikawa, and Naoto Takahashi. "Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patiens." Blood 128, no. 22 (December 2, 2016): 4240. http://dx.doi.org/10.1182/blood.v128.22.4240.4240.
Повний текст джерелаCortes, Jorge, Moshe Talpaz, Susan O’Brien, Dan Jones, Raja Luthra, Guillermo Garcia-Manero, Francis Giles, et al. "Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy." Blood 104, no. 11 (November 16, 2004): 272. http://dx.doi.org/10.1182/blood.v104.11.272.272.
Повний текст джерелаBaba, Aziz, Marjanu Hikmah Elias, Anthony Zian Au, Najlaa Maddin, Siti Maziras Makhtar, Gan Siew Hua, Azlan Husin, Sarina Sulong, Rosline Hassan, and Ravindran Ankathil. "Integrating Molecular, Epigenetic and Pharmacogenetic Approaches in Managing Imatinib Resistance Among Malaysian Chronic Myeloid Leukemia Patients." Blood 124, no. 21 (December 6, 2014): 3150. http://dx.doi.org/10.1182/blood.v124.21.3150.3150.
Повний текст джерелаSaifullah, Hilbeen Hisham, and Claire Marie Lucas. "Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?" Cancers 13, no. 16 (August 19, 2021): 4175. http://dx.doi.org/10.3390/cancers13164175.
Повний текст джерелаJankovic, Radmila, Ana Krivokuca, Ivana Boljevic, Sinisa Radulovic, and Milena Cavic. "Molecular prediction of chronic myeloid leukemia risk and resistance to imatinib." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e18543-e18543. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18543.
Повний текст джерелаStella, Stefania, Valentina Zammit, Silvia Rita Vitale, Maria Stella Pennisi, Michele Massimino, Elena Tirrò, Stefano Forte, et al. "Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib." International Journal of Molecular Sciences 20, no. 9 (May 6, 2019): 2226. http://dx.doi.org/10.3390/ijms20092226.
Повний текст джерелаEngler, Jane R., Amity Frede, Verity A. Saunders, Andrew Christopher William Zannettino, Deborah L. White, and Timothy P. Hughes. "OCT-1 Activity in CML CD34+ Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity." Blood 114, no. 22 (November 20, 2009): 2189. http://dx.doi.org/10.1182/blood.v114.22.2189.2189.
Повний текст джерелаHazazi, Ali, Mohammed Albayedh, Fawaz Albloui, and Mishal Alsulami. "Overview of Molecular Quantification of the BCR-ABL Oncogene in CML Patients." Biosciences Biotechnology Research Asia 19, no. 3 (September 29, 2022): 693–98. http://dx.doi.org/10.13005/bbra/3021.
Повний текст джерелаMillot, Frédéric, Meinolf Suttorp, Stéphanie Ragot, Guy Leverger, Jean-Hugues Dalle, Birgitta Versluijs, Birgitte Lausen, and Marina Borisevich. "Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study." Blood 136, Supplement 1 (November 5, 2020): 53–54. http://dx.doi.org/10.1182/blood-2020-135844.
Повний текст джерелаAgrawal, Mridul, Philipp Erben, Benjamin Hanfstein, Hannah Daikeler, Juliana Popa, Thomas Schenk, Armin Leitner, Richard C. Woodman, Andreas Hochhaus, and Martin C. Müller. "MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure." Blood 114, no. 22 (November 20, 2009): 2615. http://dx.doi.org/10.1182/blood.v114.22.2615.2615.
Повний текст джерелаBoender, Piet, Jeroen Janssen, Linda Smit, Rob Ruijtenbeek, Adrienne van den Berg, Rik de Wijn, and Gert J. Ossenkoppele. "Application of Kinase Activity Profiles to Predict Upcoming TKI Resistance In CML-Patients." Blood 116, no. 21 (November 19, 2010): 3425. http://dx.doi.org/10.1182/blood.v116.21.3425.3425.
Повний текст джерелаVerma, Dushyant, Hagop M. Kantarjian, Jenny Shan, Susan O'Brien, Amit Verma, Elias Jabbour, Srdan Verstovsek, Tapan Kadia, Mary Beth Rios, and Jorge Cortes. "Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?." Blood 114, no. 22 (November 20, 2009): 505. http://dx.doi.org/10.1182/blood.v114.22.505.505.
Повний текст джерелаMasuko, Masayoshi, Tatsuo Furukawa, Tadashi Koike, Kazue Takai, Koichi Nagai, Kenji Kishi, Yoshinobu Seki, et al. "Early Responses At 3 Months and 12 Months After Starting Imatinib As Predictive Factors For The Achievement Of Deep MR In Japanese CML Patients." Blood 122, no. 21 (November 15, 2013): 2744. http://dx.doi.org/10.1182/blood.v122.21.2744.2744.
Повний текст джерелаGlauche, Ingmar, Hendrik Liebscher, Christoph Baldow, Matthias Kuhn, Philipp Schulze, Tom Haehnel, Astghik Voskanyan, et al. "A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML." Blood 128, no. 22 (December 2, 2016): 3099. http://dx.doi.org/10.1182/blood.v128.22.3099.3099.
Повний текст джерелаAlaiya, Ayodele, Naeem Chaudhri, Tarek Owaidah, Jonathan Fox, Zakia Shinwari, Eman Barhoush, Fahad Alsharif, et al. "Expression Proteomics As Surrogate Biomarkers For Early Treatment Response In Chronic Myeloid Leukemia (CML) Patients." Blood 122, no. 21 (November 15, 2013): 4016. http://dx.doi.org/10.1182/blood.v122.21.4016.4016.
Повний текст джерелаMa, Jialu, Nathan Pettit, John Talburt, Shanzhi Wang, Sherman M. Weissman, and Mary Qu Yang. "Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia." International Journal of Molecular Sciences 23, no. 22 (November 18, 2022): 14335. http://dx.doi.org/10.3390/ijms232214335.
Повний текст джерелаDybko, Jaroslaw, Olga Haus, Bozena Jazwiec, Tomasz Lonc, Mateusz Sawicki, and Kazimierz Kuliczkowski. "Hasford Score Is Correlated with 18 Month Molecular Response for Chronic Myeloid Leukemia Patients Treated with Second Generation Tyrosine Kinase Inhibitors and It May be Useful to Differentiate Low and Intermediate Risk Patients: A Single Institution Experience." Blood 126, no. 23 (December 3, 2015): 5163. http://dx.doi.org/10.1182/blood.v126.23.5163.5163.
Повний текст джерелаBocchia, Monica, Anna Sicuranza, Paola Pacelli, Patrizia Pregno, Mario Annunziata, Federica Sorà, Elisabetta Abruzzese, et al. "Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation." Blood 134, Supplement_1 (November 13, 2019): 2919. http://dx.doi.org/10.1182/blood-2019-122814.
Повний текст джерелаCouto Mascarenhas, Cintia Do, Maria Helena Almeida, Eliana C. M. Miranda, Bruna Virgilio, Marcia Torresan Delamain, Gislaine O. Duarte, Vagner O. Duarte, Carmino A. De Souza, and Katia B. Pagnano. "Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line." Blood 122, no. 21 (November 15, 2013): 4041. http://dx.doi.org/10.1182/blood.v122.21.4041.4041.
Повний текст джерелаTakahashi, Naoto, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, et al. "Discontinuation of Imatinib in Japanese Patients with Chronic Myeloid Leukemia,." Blood 118, no. 21 (November 18, 2011): 3759. http://dx.doi.org/10.1182/blood.v118.21.3759.3759.
Повний текст джерелаKronenwett, Ralf, Elena Diaz-Blanco, Thorsten Graef, Ulrich Steidl, Slawomir Kliszewski, Ingmar Bruns, Frank Neumann, et al. "Molecular Phenotype of Malignant CD34+ Hematopoietic Stem and Progenitor Cells in Chronic Myelogenous Leukemia." Blood 106, no. 11 (November 16, 2005): 2863. http://dx.doi.org/10.1182/blood.v106.11.2863.2863.
Повний текст джерелаIacobucci, Ilaria, Nicoletta Testoni, Gianantonio Rosti, Marilina Amabile, Angela Poerio, Simona Soverini, Sabrina Colarossi, et al. "Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML)." Blood 106, no. 11 (November 16, 2005): 1100. http://dx.doi.org/10.1182/blood.v106.11.1100.1100.
Повний текст джерелаGaruti, Anna, Adalberto Ibatici, Gabriella Cirmena, Maurizio Miglino, Riccardo Varaldo, Colombo Nicoletta, Roberta Grasso, et al. "The Persistence of p190 BCR-ABL Transcripts Is Associated with Lower Probability of Molecular Response to Imatinib in Early and Late Chronic Phase CML Patients." Blood 106, no. 11 (November 16, 2005): 3282. http://dx.doi.org/10.1182/blood.v106.11.3282.3282.
Повний текст джерелаMarin, David, Amr R. Ibrahim, Claire Lucas, Gareth Gerrard, Lihui Wang, Richard M. Szydlo, Richard E. Clark, et al. "Assessment ofBCR-ABL1Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors." Journal of Clinical Oncology 30, no. 3 (January 20, 2012): 232–38. http://dx.doi.org/10.1200/jco.2011.38.6565.
Повний текст джерелаMarin, David, Corinne Hedgley, Richard E. Clark, Jane F. Apperley, Letizia Foroni, Dragana Milojkovic, Christopher Pocock, John M. Goldman, and Stephen O'Brien. "The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy." Blood 118, no. 21 (November 18, 2011): 785. http://dx.doi.org/10.1182/blood.v118.21.785.785.
Повний текст джерелаAlaiya, Ayodele, Mahmoud Aljurf, Zakia Shinwari, Fahad Z. Alsharif, Hazza A. Alzahrani, Syed Osman Ahmed, Tarek Owaidah, et al. "Proteomics Analysis Reveals Protein Panels That Are Associated with Prediction to Tyrosine Kinase Inhibitors Response, Bone Marrow Transplant, Survival and Disease Outcome of Chronic Myeloid Leukemia Patients." Blood 132, Supplement 1 (November 29, 2018): 5434. http://dx.doi.org/10.1182/blood-2018-99-118754.
Повний текст джерелаPicou, Frederic, Jean-Claude Chomel, Marie Christine Bene, Marc G. Berger, Thierry Fest, Valerie Ugo, Eric Lippert, et al. "Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes." Blood 132, Supplement 1 (November 29, 2018): 3024. http://dx.doi.org/10.1182/blood-2018-99-118297.
Повний текст джерелаMartynkevich, Irina, Vasily Shuvaev, Ekaterina Petrova, Lyubov Polushkina, Lyudmila Martynenko, Marina Ivanova, Natalya Cybakova, et al. "Early Molecular Response in Chronic Myeloid Leukemia Patients Predicts Future Response Status." Blood 124, no. 21 (December 6, 2014): 5529. http://dx.doi.org/10.1182/blood.v124.21.5529.5529.
Повний текст джерелаde Lavallade, Hugues, Jamshid S. Khorashad, Marco Bua, Dragana Milojkovic, Eduardo Olavarria, Alistair Reid, Jaspal S. Kaeda, John M. Goldman, Jane F. Apperley, and David Marin. "Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy." Blood 110, no. 11 (November 16, 2007): 1037. http://dx.doi.org/10.1182/blood.v110.11.1037.1037.
Повний текст джерелаEzeanosike, Obumneme B., and Onyenmechi J. Afonne. "Prognostic significance of micro RNA 150 marker in BCR-ABL positive chronic myeloid leukaemia patients on imatinib mesylate." International Journal of Contemporary Pediatrics 4, no. 5 (August 23, 2017): 1557. http://dx.doi.org/10.18203/2349-3291.ijcp20173763.
Повний текст джерелаVigneri, Paolo, Fabio Stagno, Stefania Stella, Alessandra Cupri, Michele Massimino, Agostino Antolino, Vincenzo Abbadessa, et al. "BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy." Blood 116, no. 21 (November 19, 2010): 3426. http://dx.doi.org/10.1182/blood.v116.21.3426.3426.
Повний текст джерелаEsposito, Nicola, Fabrizio Quarantelli, Luigia Luciano, Barbara Izzo, Anna Lucia Peluso, Marco Picardi, Susan Branford, et al. "The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial." Blood 112, no. 11 (November 16, 2008): 1106. http://dx.doi.org/10.1182/blood.v112.11.1106.1106.
Повний текст джерелаBranford, Susan. "Molecular monitoring in chronic myeloid leukemia—how low can you go?" Hematology 2016, no. 1 (December 2, 2016): 156–63. http://dx.doi.org/10.1182/asheducation-2016.1.156.
Повний текст джерела